- In the annual results, Pacific Edge’s total revenue increased over pcp despite the ill effects of the pandemic.
- Positive annual results expected from Comvita after registering record sales in the Chinese shopping festival.
- Lately, Radius Residential announced NZ$50 million equity raising fund for R&D activities.
Healthcare stocks are usually sturdy investments, considering the fact that the related services are always going to be in demand. Especially through the trying COVID-19 times, healthcare stocks around the world have shown an upward trend.
Image Source: © 2021 Kalkine Media
Have a look at 10 NZX-listed interesting healthcare stocks and take a peek at their latest updates.
Offering multiple retirement villages across New Zealand, Oceania healthcare Limited is meant for people in care for dementia besides other chronic conditions.
As per the results of the annual shareholders meeting held last month, there were different management changes and updates given by the Company.
During the meeting, the Company’s Chairperson discussed the annual report released for the 10-month period till 31 March 2021. He said that both the underlying EBITDA and NPAT rose by 8% and 4%, respectively on pcp.
On 23 July 2021, Oceania Healthcare was flat at NZ$1.540, at the end of the trading session.
Comvita Limited (NZX:CVT)
New Zealand-headquartered Comvita Limited provides health solutions based on the goodness of honey.
Last month, the Company noted record-breaking results in terms of sales in China’s annually held 618-shopping festival 31% on pcp. As a result, the Company has retained its FY21’s guidance and intends to resume dividend distribution as well, in anticipation of a strong result.
On 23 July 2021, Comvita up by 1.19% at NZ$3.400, at the end of the market session.
Cannasouth Limited (NZX:CBD)
Offering CBD-based medicinal use products, Cannasouth Limited, has different commercial and individual client.
In the beginning of June, the Company published an update from cannabis industry, where it was estimated that the global market for CBD products was estimated at US$13.4 billion by the onset of 2028. A CAGR of 21.2% is expected of the market expansion between the years 2021-2028.
Cannasouth has invested 3 years in building a team aiming towards generating pharmaceutical-quality cannabis for medicinal purpose. The Company also has been a leader in NZ for regulatory compliance and has various licences approved by the ministry of health.
On 23 July 2021, Cannasouth last traded at NZ$0.425, down by 1.16%.
Pacific Edge Limited (NZX:PEB)
Offering various types of cancer detection equipment, Pacific Edge Limited released its annual report in May for the period ended March 2021.
The Company’s total revenue witnessed a rise of 101% over pcp despite the ill effects of the pandemic. There was a 52% increase in customer cash receipts standing at NZ$6.7 million. Considering these findings, strong results and growth are predicted for FY22 as well.
On 23 July 2021, Pacific Edge gained 0.81% at NZ$1.24, by the end of the trading session.
Rua Bioscience Ltd (NZX:RUA)
Another Company offering cannabis-related products on this list, Rua Bioscience Limited, announced last month that it wished to partake in a two-year programme for the importance of hyperspectral technology for the cultivation of the cannabis plants.
Of late, there has been an increasing worldwide demand for cannabis for medicinal purpose. The cannabis testing sector is anticipated to be valued at US$1,806 million by the year 2025.
On 23 July 2021, Rua Bioscience closed the market session, declining by 2.38% at NZ$0.41.
Radius Residential Care Limited (NZX:RAD)
Headquartered in New Zealand, Radius Residential Care Limited provides aged care homes and special healthcare services.
Recently, the Company announced equity raising of a huge NZ$50 million fund for different growth-related activities. This would include the purchase of different buildings, which are not currently owned by the Company but work under the same aged care structure pattern.
On 23 July 2021, Radius Residential Care was flat at NZ$0.820, by the end of the market session.
Ryman Healthcare Limited (NZX:RYM)
With over 36 old age villages across the nation, Ryman Healthcare Limited is the leader in the business.
In the 2021 annual report of the Company for period till 31 March 2021, the underlying profit was determined NZ$224.4 million, while the IFRS profit was found to be NZ$423.1 million. Also, the Company gave out a dividend of 22.4 cents for the entire year.
On 23 July 2021, Ryman Healthcare was down by 0.53% at NZ$13.02, at the end of the trading session.
Promisia Healthcare Limited (NZX:PHL)
Nature-based products provider Promisia Healthcare Limited ensures that it undergoes safety and efficiency tests. The annual report published by the Company for the period till 15 March 2021 witnessed a revenue of NZ$6.0 million, NPAT of NZ$0.02 million and a net debt of NZ$17.8 million. The total assets were valued at NZ$59.2 million.
Promisia Healthcare was flat at NZ$0.002, by the time, the market closed on 23 July.
Blis Technologies Limited (NZX:BLT)
New Zealand-based Blis Technologies Limited famously offers skincare and healthcare products based on their original probiotic strains.
In the financial results for FY21 released by the Company, for the period till 31 March 2021, it was found that the revenue is recorded at NZ$10.6 million, while the EBITDA was NZ$1.0 million. The net profit was recorded at NZ$0.6 million while the ingredient-based revenue recorded an increase of 12%.
On 23 July 2021, Blis Technologies was up by 1.39% at NZ$0.073, by the end of the market session.
Offering medical-based equipment for commercial and home settings alike, Fisher and Paykel Healthcare Limited noted an 82% increase in the net profit in the full-year results for the period ending 31 March.
The Company’s operating revenue recorded was NZ$1.97 billion. Merely in the hospital-based product business, the Company witnessed an 87% growth standing at NZ$1.50 billion.
On 23 July 2021, Fisher and Paykel closed the day’s trading session at NZ$32.65, up by 3.16%.